KR20160015988A - Composition for the prevention or treatment of periodontal disease comprising extract of Fermented Ponciri Fructus - Google Patents

Abstract

Provided in the present invention is a composition, comprising a fermented extract of Ponciri Fructus as an active ingredient for preventing, alleviating, or treating periodontal diseases. The fermented extract of Ponciri Fructus of the present invention is effective in preventing and treating periodontal diseases, by introducing cytodifferentiation of periodontal cells, enhancing mineralization of bones, regenerating an alveolar bone, and promoting anti-inflammatory and antimicrobial effects.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing or treating periodontal disease, comprising fermented persimmon extract as an active ingredient,

The present invention relates to a composition comprising a fermentation yeast extract for preventing or treating periodontal disease as an effective ingredient.

The teeth are the hardest hard tissue in the human body and are supported on the alveolar bone. The alveolar bone is firmly attached to the base bone of the jaw, and the 2-3 mm portion immediately adjacent to the root is called a periodontal bone, but the alveolar bone generally refers to both the hard tissue including the periodontal bone. Alveolar bone is gradually lowered with age, and tooth root is exposed. In addition, when the tooth is lost, the alveolar bone gradually disappears. These oral alveolar bone attaches and supports the teeth by a layer of undifferentiated mesenchymal cells called periodontal ligaments with an average thickness of about 0.2 mm and distributes the force to the alveolar bone so that the teeth can buffer during food chewing And the sense of teeth is transmitted to the alveolar bone through the periodontal ligament. In addition, periodontal ligaments are structured to adapt to pressure, continuing bone remodeling, without destroying the structure and function of the entire fiber, continuing to layers of undifferentiated mesenchymal cells. Undifferentiated mesenchymal cells in periodontal ligaments are moved to adjacent tissues, moving to the alveolar bone to perform alveolar bone remodeling and, on the other hand, move to the teeth to produce collagen fibers, which are constantly modified to hold the teeth more tightly. These teeth are allied with osteoblast-induced bone formation and osteoclast-induced bone resorption in the alveolar bone, and are maintained in balance through continuous remodeling.

Periodontal diseases include gingivitis and periodontitis, which affect teeth and gingiva supporting the teeth. Gingivitis is an early periodontal disease that causes inflammation of the soft tissues of the gingiva, and its symptoms are relatively light and the recovery is reversible. Periodontitis is a condition in which gingivitis is not treated and the inflammation progresses to the gums and around the pubic bone. When the chronic inflammatory reaction stimulated by the bacterial toxin develops, the periodontal pocket is formed between the gums and the teeth and the periodontal pocket is formed. Deepening of the depth of the periodontal ligament results in inflammation of the periodontal ligament and bone loss. In addition, osteoblast-induced osteoblast-induced osteoblast-induced osteoblast-like metabolism by osteoblast-like cells causes osteoblast-like disorders such as osteoporosis when bone mass exceeds bone formation due to various factors.

Treatment of periodontal disease has been based on the establishment of improved oral hygiene in patients, non-surgical or surgical calculus removal, root resorption, gingival curettage, and regeneration of periodontal tissue using neoadjuvant. However, these surgical treatment methods are difficult to treat, effective treatment is difficult, and the disease is limited to the treatment that is performed when the disease progresses rather than the prevention, and most cases are chronic when not treated. In addition, systemic antibiotics and local sustained release agents have been used as adjunctive therapies. However, excessive release of drugs to unnecessary sites has resulted in side effects, and a case in which periodontal disease bacteria showing resistance to recently used antibiotics have been isolated It is reported that it has a serious problem. In addition, periodontal disease is characterized by multiple factors such as loss of alveolar bone, inflammation, and periodontitis bacteria such as Jinji valis unlike general inflammation and arthritis. Therefore, periodontal disease is caused by antibacterial and anti-inflammatory, Although a complex treatment method is required, there is no developed drug or therapeutic method for such treatment.

Under such circumstances, it is necessary to develop a drug or a therapeutic agent capable of effectively treating periodontal disease.

KR 10-2013-0128953, 2013.11.27 KR 10-1354923, 2014.01.17

The present invention provides a composition for prevention or treatment of periodontal disease, which comprises fermented persimmon extract as an active ingredient. The present invention also provides an oral composition for the prevention and treatment of periodontal disease, which comprises fermented persimmon extract as an active ingredient. The present invention also provides a health functional food for preventing or ameliorating periodontal disease, which comprises fermented persimmon extract as an active ingredient.

The inventors of the present invention discovered that fermented wipes have a remarkable effect on the treatment and prevention of periodontal disease while studying to develop a natural medicinal composition having a therapeutic and preventive effect on periodontal disease, and completed the present invention.

The extract of the present invention has no side effects and is a preventive and therapeutic agent for periodontal disease using a fermented fibrin which is a safe natural agent.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing or treating periodontal disease, comprising fermented Zygomycetes extract as an active ingredient.

The pharmaceutical composition for preventing or treating periodontal disease containing the fermented persimmon extract of the present invention as an active ingredient can be used for the prevention and treatment of periodontal disease through the enhancement of mineralization by the increase of alkaline phosphatase and the anti- .

In the present invention, the fibril is dried by drying the young fruit of the tangerine tree. The scientific name of Poncirus trifoliata is Rafinesqul and its common name is Ponciri Fructus . It is a deciduous broad-leaved arboreous tree which grows in the islands of Jeju-do and Gadukdo in southern part of Korea. It is about 3 m tall. Leaves are hyeogen and have three leaflets. Flowers are white, and flowers bloom earlier than leaves in spring, no peduncle, 5 calyxes, 5 petals. The fruit is round and round in shape, 3-4 cm in diameter, yellow, ripe, fragrant, flowering period 3-5 months, fruit season 9-11.

In the present invention, fermentation refers to a process in which a microorganism decomposes an organic substance using an enzyme contained therein. In the present invention, the fermented persimmon extract is obtained by treating microorganisms with persimmon extracts. When the persimmon extracts are physically or chemically modified by fermentation, the extracts having a high content of active ingredients are obtained.

In the present invention, the fermentation yeast extract may be a fermentation broth fermented using lactic acid bacteria or a semi-dried or dried powder of the fermentation broth. In the present invention, lactic acid bacteria are collectively referred to as bacteria that ferment a saccharide to obtain energy and produce a large amount of lactic acid. For example, lactic acid bacteria such as Lactobacillus , Lactococcus, Leuconostoc, Pediococcus, and Bifidobacterium lactic acid bacteria. The lactic acid bacteria are preferably Lactobacillus, more preferably Lactobacillus brevis , and even more preferably Lactobacillus brevis THK-734 ( Lactobacillus brevis ) brevis THK- 734 ) KCTC 12637BP.

In the present invention, periodontal disease includes gingivitis, periodontal inflammation, alveolar bone breakage, or alveolar bone osteodystrophy, and is preferably periodontitis. In addition, the alveolar bone formation disorder includes alveolar bone osteoporosis, alveolar bone osteomalacia, or alveolar bone osteopenia.

In the present invention, prevention or treatment of periodontal disease may be due to mineralization enhancement, antibacterial activity, and anti-inflammatory effect in the alveolar bone.

In the present invention, the extraction method such as hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction can be used. The number of extraction times is preferably 1 to 5 times, but is not limited thereto. The extract can be filtered or concentrated and extracted with filtration or concentration in liquid or powder form. The extraction solvent may be selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, and an aqueous alcohol solution having 1 to 4 carbon atoms. Preferably, the extraction solvent may be water. In the hot water extraction, the extraction can be carried out at 60 to 100 DEG C for 1 to 24 hours, and the amount of the extraction solvent is 2 to 15 times the dry weight of the bed. The root extract has an amount of 0.1 to 95% by weight based on the total weight of the root extract.

The flax extract extracted by the above extraction method can be used as lactic acid bacteria of 1 to 20% (v / v), for example, Lactobacillus , Lactococcus, Leuconostoc, Pediococcus, Lactic acid bacteria in Bifidobacterium, preferably Lactobacillus brevis brevis , more preferably Lactobacillus brevis THK-734 ( Lactobacillus brevis THK- 734 ) KCTC 12637BP, and can be fermented by incubation for 1 to 10 days in a 20 ° C to 40 ° C incubator. The fermented unsubstituted extract may be filtered to remove the cells, and concentrated or lyophilized.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive. Examples of the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, Wherein the starch is selected from the group consisting of lactose, mannitol, sugar, arabic gum, pregelatinized starch, cornstarch, powdered cellulose, hydroxypropyl cellulose, opaques, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, Calcium, white sugar, dextrose, sorbitol and talc may be used.

The pharmaceutically acceptable additives according to the present invention are preferably contained in an amount of 0.1 to 90 parts by weight based on 100 parts by weight of the fermented Zygomycota extract, but the present invention is not limited thereto.

That is, the pharmaceutical composition of the present invention can be administered in various formulations of oral and parenteral administration in actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, May be formulated using excipients. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are commonly used simple diluents . Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, and freeze-drying agents. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent.

The pharmaceutical composition of the present invention may be orally administered or parenterally administered according to the desired method, and may be administered orally or parenterally in the case of parenteral administration by external or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, It is desirable to select the method. The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.

The dosage of the pharmaceutical composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, Kg, preferably 0.01 to 100 mg / kg, and may be administered 1 to 6 times a day.

The present invention provides an oral composition for prevention and improvement of periodontal disease, which comprises fermented persimmon extract as an active ingredient.

As used herein, "oral composition" is a composition which is put into oral form with mineralization enhancement, antibacterial and anti-inflammatory effects in alveolar bone. In the oral composition of the present invention, the formulations may be formulated into, for example, films, toothpastes, mouthwashes, ointments, sprayings, dressing solutions, coatings, dental floss or periodontal pouches.

The composition for oral administration of the present invention may contain a fermented persimmon extract as an active ingredient and may further contain a wetting agent, a foaming agent, a preservative, a sweetening agent, a thickening agent, a water-soluble polymer, a perfume and other ingredients. The additive according to the present invention is preferably contained in an amount of 0.1 to 90 parts by weight based on 100 parts by weight of the fermented Zygomycota extract, but is not limited thereto.

The wetting agent may be at least one selected from the group consisting of polyhydric alcohols such as glycerin, sorbitol solution, amorphous sorbitol solution, polyethylene glycol and propylene glycol as a component for suppressing the evaporation of water in the oral composition.

The foaming agent has an effect of emulsifying or solubilizing a water-soluble component and an oil-soluble component in the composition, and has a cleaning effect in the oral cavity. Examples of the foaming agent include sodium lauryl sulfate, sodium N-lauroylsartocate, N- Anionic surfactants such as sucrose fatty acid esters, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid esters, polyoxyethylene polyoxypropylene copolymers, and the like may be mixed and used.

 The preservative is a component for prolonging the preservation period, and methyl paraoxybenzoate, benzoic acid, sodium benzoate and the like can be used.

The sweetener and / or fragrance may be saccharin sodium, aspartame, stevioside, licorice acid, and the like. Examples of the sweetener include peppermint, spearmint oil, Menthol, carbo- nons, anethole, and augenol.

The thickening agent is a component which prevents phase separation depending on time by combining the water-insoluble inorganic powder component and the liquid component in the composition and gives a viscosity to the composition. Examples of the component include carboxymethyl cellulose (CMC), carrageenan, sodium alginate, Rubber, xanthan gum, other gums and the like may be mixed and used.

The water-soluble polymer may be selected from the group consisting of hydroxypropyl cellulose-Klucel (TM), hydroxypropyl methylcellulose, hydroxyethyl cellulose, ethyl cellulose, carboxymethylcellulose, dextran Dextran, gaur-gum, polyvinyl pyrrolidone (PVP), pectins, starches, gelatin, casein, sodium alginate, polyethlyene glycol, , Polyvinyl glycol, and the like may be used in combination.

As other additives, stabilizers such as sodium citrate for pH control, fluorinating agents having a cavity inhibiting function, astringent agents such as zinc chloride, and food colors such as blue No. 1 can be used.

The present invention also provides a health functional food for preventing or ameliorating periodontal disease containing fermented persimmon extract as an active ingredient.

The fermented milk extract of the present invention can be used as it is or can be used in combination with other food or food ingredients, and can be suitably used according to conventional methods.

There is no particular limitation on the kind of the food. Examples of the food to which the fermented persimmon extract can be added include dairy products such as meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

In addition to the above, the fermented persimmon extract of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the fermented persimmon extract of the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination.

The composition comprising the fermented zucchini extract of the present invention as an active ingredient induces differentiation of periodontal cells, promotes mineralization of bone, regenerates alveolar bone, promotes anti-inflammatory and antibacterial effects, It is effective for treatment.

Fig. 1 shows the results of measurement of nitrogen monoxide production by treating fermented persimmon extract.
FIG. 2 shows the result of measuring the activity (ALP) of alkaline phosphatase, which is an osteoblast differentiation marking factor, by treating fermented persimmon extract.
FIG. 3 shows the result of measuring the mineralization activity by treating the fermented persimmon extract.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.

<Preparation Example> Preparation of fermented persimmon extract

The new strain from kimchi was named Lactobacillus brevis THK-734 ( Lactobacillus brevis THK-734 ) and deposited with Korea Research Institute of Bioscience and Biotechnology as the deposit number KCTC 12637BP. The Lactobacillus brevis THK-734 KCTC 12637BP was inoculated in MRS broth at a concentration of 1% (w / v) and cultured in a 30 ° C. incubator for 48 hours.

1 kg was ground to a size of 10-20 mm to prepare a sample. To 500 g of the sample, 10 times as much water as water was added, and the mixture was subjected to hot water extraction at 85 ° C, followed by extraction for 4 hours and filtration.

The above goat extract was inoculated with 5% (v / v) of the Lactobacillus brevis THC-734 (KCTC 12637BP) culture solution for 5 days in a 30 ° C. incubator, and then filtered to remove the cells. To prepare fermented persimmon extract.

As a control, the extract of Fusarium wilt was prepared by directly lyophilizing the hot-water extract except for the step of inoculation with Lactobacillus brevis THK-734 ( Lactobacillus brevis THK-734 ) KCTC 12637BP.

Example 1 Confirmation of Nitric Oxide Decrease by Treatment with Fermented Zygomycetes Extract

It has been reported that nitric oxide (NO) at a high concentration induces an inflammatory reaction to inhibit the proliferation and differentiation of periodontal ligament cells, while a low concentration of nitrogen monoxide (NO) inhibits the inflammatory response and stimulates the function of periodontal ligament cells have. Therefore, it was evaluated whether the fermented persimmon extract of the present invention inhibited NO production.

The NO assay was performed by a modification of the method described by Sherman et al. (Biochem. Biophys. Res. Commun. 191, p1301-1308, 1993).

RAW 264.7 cell line, a mouse macrophage line, was inoculated at 2.5 × 10 ⁵ cells / ml into a 48 well plate containing DMEM containing 10% fetal bovine serum (Dulbecco's Modified Eagle's medium, Cambrex, USA) (10 ng / ml) was added to the second group to induce macrophage activation, and the third group was further divided into three groups to obtain fermented yeast extract (10 ng / ml) in the group 3-1, 10 μg / ml in the group 3-2, and 100 μg / ml in the group 3-3, respectively. Each was incubated in a carbon dioxide incubator (5% CO 2, 95% relative humidity, 37 ° C) for 24 hours.

Each of the above culture solutions was supplemented with a grease reagent (37.5 mM sulphanilic acid, 12.5 mM N- (1-naphthyl) ethylenediamine dihydride, 6.5 mM hydrochloric acid ]), And then the absorbance was measured at 550 nm using a spectrophotometer. The concentration of NO ₂ produced by RAW 264.7 cells in the culture was calculated based on the NO ₂ -concentration-absorbance correlation coefficient generated using nitrate of 0 to 50 μM concentration.

The results are shown in Fig. 1 shows that the fermented persimmon extract significantly inhibited the production of NO in a concentration-dependent manner (in FIG. 1, * indicates p-value <0.05 and ** indicates p-value <0.01).

From the above results, it was confirmed that the fermented yeast extract of the present invention inhibited NO production, suppressed the inflammatory reaction, stimulated the action of periodontal ligament cells, and further enhanced the content of active ingredients through the fermentation process, .

< Example  2> Alkaline Phosphatase Activity by Fermented Zygotic Extract Treatment Alkaline 포스화제 activity ) Confirm

The effect of fermented Zyprexa extract on alkaline phosphatase activity was confirmed, and the effect of fermented Zygomycota extract on the prevention and treatment of periodontal disease was confirmed by the osteoblast differentiation and mineralization promoting effect.

Human periodontal ligament cells (Periodontal ligament progenitor cells (PDLC) ) with 10% FBS (fetal bovine serum; FBS), 100 IU / ml penicillin and 100 ug / ml streptomycin into the DMEM medium is added 5% CO ₂ , And cultured in a cell incubator under the condition of 37 캜. The cultured cells were treated at a concentration of 1 × 10 ⁵ cells / ml in a 24-well plate and cultured in a cell incubator for 24 hours.

In order to confirm the alkaline phosphatase activity of periodontal ligament cells, the cells were treated with 1, 10, and 100 ug / ml of fermented Zygomycetum extract and then cultured for 72 hours, and the activity of the cells was measured. To measure alkaline phosphatase activity, the medium was removed from the plate, washed three times with PBS, and 50 μl of 0.15% Triton X-100 was added thereto, followed by lysis in a 37 ° C incubator for 30 minutes. After centrifugation at 3,000 rpm for 5 minutes, 40 μl of supernatant, 40 μl of 0.1 N glycine, and 20 μl of 100 mM p-nitrophenylphosphate (p-NPP) were added and reacted for 30 minutes at 37 ° C. After the reaction, 50 μl of 0.1 N NaOH was added to stop the reaction, and the absorbance at 405 nm was measured to calculate the amount of p-NPP converted to p-nitrophenol (p-NP) by ALP enzyme. The results are shown in Fig. (In Fig. 2, ** indicates p-value < 0.01, *** indicates p-value < 0.001)

As shown in FIG. 2, the activity of alkaline phosphatase, which is an indicator of periodontal ligament cell differentiation, was increased by 8.9%, 6.4%, and 11.4% at the concentrations of 1, 10, and 100 ug / ml, respectively. That is, the fermented zucchini extract was found to be effective in preventing and treating periodontal disease by inducing an increase in activity of alkaline phosphatase, and further enhancing the content of active ingredients through the fermentation process, .

< Example  3> Mineralization activity  Confirm

The periodontal ligament cells produce calcium and release it outside the cell. In the culture medium for periodontal ligament cells, mineralization occurs in which calcium accumulates around the cells. In this regard, it was evaluated whether the fermented zucchini extract of the present invention increased the mineralization of periodontal ligament cells.

Human periodontal ligament cells (Periodontal ligament progenitor cells (PDLC) ) with 10% FBS (fetal bovine serum; FBS), 100 IU / ml penicillin and 100 ug / ml streptomycin into the DMEM medium is added 5% CO ₂ , And cultured in a cell incubator maintained at 37 ° C. The cultured cells were subcultured in a 24-well plate at 1 × 10 ⁵ cells / ml and cultured in the cell incubator for 24 hours.

The periodontal ligament cells were activated by adding ascorbic acid and beta-glycerophosphate, known to activate periodontal ligament cells, to the medium at concentrations of 50 μg / ml and 10 mM, respectively. The activated cells were divided into two groups. No substance was added to the first group (control group), and the second group was further divided into three groups, with 1 μg / ml for the 2-1 group and 5 μg for the 2-2 group / ml, and in group 2-3, 10 μg / ml fermented Zygomycetes extract was added to the culture medium. And the medium was replaced with the medium containing the fermentation yeast extract at intervals of 3 days and cultured for 24 days.

After each cell was fixed with 10% neutral formaldehyde solution, it was treated with Alizarin red-S staining solution for 5 minutes and washed to determine whether a red color calcified nodule was formed Respectively. After confirming nodule formation, 10 mM sodium phosphate (10% cetylpyridinium chloride, pH 7.0) was added at 1 ml / well and absorbance was measured at 550 nm with an ELISA reader. The results are shown in Fig. (In Fig. 3, * indicates p-value < 0.05, ** indicates p-value < 0.01, and *** indicates p-value < 0.001).

As shown in FIG. 3, the mineralization of the fermented persimmon extract was increased by 22.7%, 44.9% and 51.5% at 1, 5 and 10 ㎍ / ㎖, respectively, as compared with the control. In other words, the fermented persimmon extract was found to be effective for the prevention and treatment of periodontal disease by promoting mineralization. Particularly, it was confirmed that by further increasing the content of active ingredients through the fermentation process, the effect was even greater than that of the general waste paper.

Korea Biotechnology Research Institute KCTC12637BP 20140729

Claims (9)

A pharmaceutical composition for preventing or treating periodontal disease, comprising fermented persimmon extract as an active ingredient. [Claim 2] The pharmaceutical composition according to claim 1, wherein the fermented persimmon extract is a fermentation broth fermented using lactic acid bacteria, a semi-dried or dried powder of a fermentation broth. The method of claim 2, wherein the lactic acid bacteria are selected from among lactic acid bacteria selected from the group consisting of Lactobacillus , Lactococcus, Leuconostoc, Pediococcus, and Bifidobacterium A pharmaceutical composition. 4. The method of claim 3 wherein the Lactobacillus is Lactobacillus brevis THK -734 (Lactobacillus brevis THK- 734 ) KCTC 12637BP. The pharmaceutical composition according to claim 1, wherein the periodontal disease is selected from the group consisting of gingivitis, periodontal inflammation, alveolar bone breakage, and alveolar bone osteodystrophy. The pharmaceutical composition according to claim 1, wherein the prevention and treatment of periodontal disease is prevention and treatment by any one or more selected from the group consisting of mineralization enhancement, antibacterial activity, or anti-inflammatory effect in alveolar bone. The pharmaceutical composition according to claim 1, wherein the extract is extracted with at least one solvent selected from water, an alcohol having 1 to 4 carbon atoms, and an aqueous solution of an alcohol having 1 to 4 carbon atoms. A composition for oral administration for prevention and improvement of periodontal disease containing fermented persimmon extract as an active ingredient. A functional food for prevention and improvement of periodontal disease containing fermented persimmon extract as an active ingredient.

Images